Quantifying Preference Values for Non-metastatic Castration-resistant Prostate Cancer Treatments using Discrete Choice Experiments

Related videos

Bayer
Preference Values in Treatment of Non-metastatic Castration-Resistant prostate Cancer for HTA - The Patient Perspective
Nov 04, 2020
Bayer
Preference Values in Treatment of Non-metastatic Castration-Resistant prostate Cancer for HTA - The Physician Perspective
Nov 04, 2020
Bayer
The Importance of Identifying Patients who may Benefit from Precision Oncology Medicines
Nov 03, 2020
Bayer
Precision Oncology Medicines: Changing the Cancer Treatment Landscape
Nov 03, 2020
Bayer
Precision Oncology Medicines: A New Era in the Treatment of Cancer Patients
Nov 03, 2020
Association of European Cancer Leagues (ECL)
ECL Access to Medicines Task Force
Oct 02, 2020